TZTing-Ting Zhao

Ting-Ting Zhao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ting-Ting Zhao has a total of 24 co-authors. Here are the top co-authors by number of shared publications:

  • Hao Xu

    Department of Medical Oncology, Shengjing Hospital of China Medical University, Shenyang, Liaoning Province, China

    2 shared publications
  • Hui-Mian Xu

    Department of Surgical Oncology, First Hospital of China Medical University, Shenyang, Liaoning Province, China

    2 shared publications
  • Xing-Yu Liu

    Department of Surgical Oncology, First Hospital of China Medical University, Shenyang, Liaoning Province, China

    2 shared publications
  • Yingying Xu

    Department of Breast Surgery, The First Hospital of China Medical University, Shenyang, Liaoning Province, China.

    2 shared publications
  • Yongxi Song

    Department of Surgical Oncology and General Surgery, The First Hospital of China Medical University, Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors (China Medical University), Ministry of Education, 155 North Nanjing Street, Heping District, Shenyang, 110001, China

    2 shared publications
  • Zhenning Wang

    Department of Surgical Oncology and General Surgery, The First Affiliated Hospital of China Medical University, Shenyang, China

    2 shared publications

Latest Publications

  • Open Access

    Exploring the applications of gastric organoids in disease modeling and personalized medicine

    by Xin-Ru Mu, Li-Li Wang, Min-Jiao Pang, Qi-Yue Tong, Jia-Ning Zhang, Zhao-Long Li, Meng Yuan, Wen-Tao Chen, Zhi-Feng Miao, Ting-Ting Zhao

    Organoid systems are capable of forming three-dimensional self-organizing structures that closely recapitulate the cellular composition and physiological functions of native gastric tissue. Since their introduction, gastric organoid technology has rapidly advanced and become a powerful tool for studying gastric development, disease mechanisms, and therapeutic responses. This review summarizes key developments in the field, with a focus on five major areas of application: gastric developmental biology, modeling of Helicobacter pylori infection, research on gastric cancer and drug resistance, assessment of personalized therapy, and regenerative medicine. Distinct from previous reviews, this article systematically traces the evolution of gastric organoid technology and provides an in-depth analysis of current limitations in microenvironment reconstruction, standardized culture, immune co-culture modeling, and clinical translation. In addition, it discusses emerging strategies and integrated technologies aimed at overcoming these challenges, offering perspectives to advance organoid systems from basic research toward clinical application.


  • Open Access

    Cellular plasticity and fate determination in gastric carcinogenesis

    by Zheng He, Xiao-Hai Hu, Tian-Yu He, Ting-Ting Zhao


  • Open Access

    The role of EGFR mutation as a prognostic factor in survival after diagnosis of brain metastasis in non-small cell lung cancer: a systematic review and meta-analysis

    by Wen-Ya Li, Ting-Ting Zhao, Hui-Mian Xu, Zhen-Ning Wang, Ying-Ying Xu, Yunan Han, Yong-Xi Song, Jian-Hua Wu, Hao Xu, Song-Cheng Yin, et al.

    The brain is a common site for metastasis in non-small-cell lung cancer (NSCLC). This study was designed to evaluate the relationship between the mutational of the epidermal growth factor receptor (EGFR) and overall survival (OS) in NSCLC patients with brain metastases. Searches were performed in PubMed, EmBase, and the Cochrane Library to identify studies evaluating the association of EGFR mutation with OS in NSCLC patients through September 2017. 4373 NSCLC patients with brain metastases in 18 studies were involved. Mutated EGFR associated with significantly improved OS compared with wild type. Subgroup analyses suggested that this relationship persisted in studies conducted in Eastern, with retrospective design, with sample size ≥500, mean age of patients ≥65.0 years, percentage male < 50.0%, percentage of patients receiving tyrosine kinase inhibitor ≥30.0%. Finally, although significant publication bias was observed using the Egger test, the results were not changed after adjustment using the trim and fill method. This meta-analysis suggests that EGFR mutation is an important predictive factor linked to improved OS for NSCLC patients with brain metastases. It can serve as a useful index in the prognostic assessment of NSCLC patients with brain metastases.


  • Open Access

    Effect of neoadjuvant chemotherapy in patients with gastric cancer: a PRISMA-compliant systematic review and meta-analysis

    by Zhi-Feng Miao, Xing-Yu Liu, Zhen-Ning Wang, Ting-Ting Zhao, Ying-Ying Xu, Yong-Xi Song, Jin-Yu Huang, Hao Xu, Hui-Mian Xu

    Neoadjuvant chemotherapy (NAC) is extensively used in the treatment of patients with gastric cancer (GC), particularly in high risk, advanced gastric cancer. Previous trials testing the efficacy of NAC have reported inconsistent results. This study compares the combined use of NAC and surgery with surgery alone for GC by using a meta-analytic approach. We performed an electronic search of PubMed, EmBase, and the Cochrane Library to identify randomized controlled trials (RCTs) on NAC published before Oct 2015. The primary outcome of the studies was data on survival rates for patients with GC. The summary results were pooled using the random-effects model. We included 12 prospective RCTs reporting data on 1538 GC patients. Patients who received NAC were associated with significant improvement of OS (P = 0.001) and PFS (P < 0.001). Furthermore, NAC therapy significantly increased the incidence of 1-year survival rate (SR) (P = 0.020), 3-year SR (P = 0.011), and 4-year SR (P = 0.001). Similarly, NAC therapy was associated with a lower incidence of 1-year (P < 0.001), 2-year (P < 0.001), 3-year (P < 0.001), 4-year (P = 0.001), and 5-year recurrence rate (P = 0.002). Conversely, patients who received NAC also experienced a significantly increased risk of lymphocytopenia (P = 0.003), and hemoglobinopathy (P = 0.021). The findings of this study suggested that NAC is associated with significant improvement in the outcomes of survival and disease progression for GC patients while also increasing some toxicity.